Last reviewed 2026-04-20 · How we verify

Dose level 4 group

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Nasopharyngitis
• Pyrexia
• Diarrhoea
• Anaemia
• Gastroenteritis
• Bronchiolitis
• Pain
• Pharyngitis
• Irritability
• Viral infection
• Pharyngotonsillitis
• Conjunctivitis

Key clinical trials

• A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
• A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus (PHASE1)
• A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (PHASE3)
• Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers (PHASE1)
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants (PHASE2)
• Toddler Biomarker of Nutrition Study (NA)
• Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors (PHASE1)
• Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Dose level 4 group CI brief — competitive landscape report
• Dose level 4 group updates RSS · CI watch RSS
• Ting Chang, MD portfolio CI